Azithromycin News and Research

RSS
Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
Template for COVID-19 management in a rural health system

Template for COVID-19 management in a rural health system

News coverage contributes to drug shortages in COVID-19

News coverage contributes to drug shortages in COVID-19

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

Azithromycin use for treating COVID-19 may increase risk of cardiac events

Azithromycin use for treating COVID-19 may increase risk of cardiac events

AI and machine learning tools can help separate COVID-related claims

AI and machine learning tools can help separate COVID-related claims

Identifying, preventing and treating drug-induced arrhythmias

Identifying, preventing and treating drug-induced arrhythmias

Study: Hydroxychloroquine plus azithromycin linked to significant cardiovascular risks

Study: Hydroxychloroquine plus azithromycin linked to significant cardiovascular risks

Study: Frequent use of antimicrobial drugs impairs bacterial diversity in saliva

Study: Frequent use of antimicrobial drugs impairs bacterial diversity in saliva

Cardiovascular disease in COVID-19

Cardiovascular disease in COVID-19

Oxford University and ZOE join forces to widen access to COVID-19 treatment trials

Oxford University and ZOE join forces to widen access to COVID-19 treatment trials

Clinical trials of hydroxychloroquine in COVID-19 outpatients reported as safe

Clinical trials of hydroxychloroquine in COVID-19 outpatients reported as safe

Prednisone, Hydroxychloroquine best among COVID-19 treatments, claims large Spanish study

Prednisone, Hydroxychloroquine best among COVID-19 treatments, claims large Spanish study

Study identifies factors associated with death in critically ill COVID-19 patients

Study identifies factors associated with death in critically ill COVID-19 patients

Dutch trial of convalescent plasma in COVID-19 discontinued

Dutch trial of convalescent plasma in COVID-19 discontinued

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

Low potassium levels in COVID-19 disease

Low potassium levels in COVID-19 disease

Life saving drug found for COVID-19 patients on ventilators

Life saving drug found for COVID-19 patients on ventilators

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

Hydroxychloroquine shows no antiviral effect on SARS-Cov-2 in non-human primate models

Hydroxychloroquine shows no antiviral effect on SARS-Cov-2 in non-human primate models

Anticardiolipin antibodies and COVID-19

Anticardiolipin antibodies and COVID-19